Altimmune (ALT) Non-Current Deffered Revenue (2010 - 2018)

Altimmune (ALT) has reported Non-Current Deffered Revenue for 5 consecutive years, with $1.0 million the latest figure, recorded in Q4 2018.

• In Q4 2018, Non-Current Deffered Revenue rose 170.59% year-over-year to $1.0 million; the TTM figure through Dec 2018 stood at $1.0 million (up 170.59% YoY), while the FY2018 annual figure was $1.0 million, up 170.59% from the prior year.
• Non-Current Deffered Revenue fell to $1.0 million in Q4 2018 per ALT's latest filing, from $1.1 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $1.1 million in Q1 2018 and bottomed at $15914.0 in Q4 2016.
• Historically, Non-Current Deffered Revenue has averaged $517522.2 across 3 years, with a median of $278018.0 in 2017.
• Annual changes were most pronounced in 2017 — Non-Current Deffered Revenue soared 2328.61% — and 2018, when it retreated 11.66%.
• Altimmune's Non-Current Deffered Revenue stood at $15914.0 in 2016, then jumped by 2328.61% to $386489.0 in 2017, then soared by 170.59% to $1.0 million in 2018.
• Business Quant data shows ALT's Non-Current Deffered Revenue at $1.0 million in Q4 2018, $1.1 million in Q3 2018, and $149785.0 in Q2 2018.